To inhibit CCL2 and its cognate receptor CCR2 axis, Shen et al. synthesized siCCR2-encapsulated cationic nanoparticle (CNP/siCCR2) to inhibit primary tumor progression and further metastasis by reducing the abundance of TAMs and altering the immunosuppressive tumor microenvironment (Shen et al., 2018). This evidence concerns the gene CCL2 and neoplasm.